Breaking News, Financial News

Financial Report: Charles River 3Q

Preclinical Services up 6% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories 3Q Revenues: $278.7 million (flat) 3Q Earnings: $22.2 million (+17%) YTD Revenues: $849.4 million (flat) YTD Earnings: $79.3 million (-4%) Comments: Research Models and Services (RMS) segment sales were $166.5 million in the quarter, down 3%. Preclinical Services (PCS) sales were $112.2 million, up 6%. Income from continuing operations for the quarter was $22.4 million, compared to $18.9 million in 3Q11....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters